A subset of integrin ␣ subunits contain an I domain, which is important for ligand binding. We have deleted the I domain from the ␤2 integrin lymphocyte function-asssociated antigen-1 (LFA-1) and expressed the resulting non-I domain-containing integrin (⌬I-LFA-1) in an LFA-1-deficient T cell line. ⌬I-LFA-1 showed no recognition of LFA-1 ligands, confirming the essential role of the I domain in ligand binding. Except for I domain monoclonal antibodies (mAbs), ⌬I-LFA-1 was recognized by a panel of anti-LFA-1 mAbs similarly to wild-type LFA-1. However, ⌬I-LFA-1 had enhanced expression of seven mAb epitopes that are associated with ␤2 integrin activation, suggesting that it exhibited an "active" conformation. In keeping with this characteristic, ⌬I-LFA-1 induced constitutive activation of ␣4␤1 and ␣5␤1, suggesting intracellular signaling to these integrins. This "cross-talk" was not due to an effect on ␤1 integrin affinity. However, the enhanced activity was susceptible to inhibition by cytochalasin D, indicating a role for the cytoskeleton, and also correlated with clustering of ␤1 integrins. Thus, removal of the I domain from LFA-1 created an integrin with the hallmarks of a constitutively active receptor mediating signals into the cell. These findings suggest a key role for the I domain in controlling integrin activity.
INTRODUCTION
The integrin lymphocyte function-associated antigen-1 (LFA-1) (␣L/␤2, CD11a/CD18) is a leukocyte-specific receptor that mediates cell-cell interactions in the immune system (reviewed by Gahmberg, 1997) . The ligands for LFA-1 are three members of the Ig superfamily of proteins, intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3. The extracellular portions of the ␣ and ␤ subunits of integrins consist of several types of domains. The N termini of the ␣ subunits contain seven homologous repeats of ϳ60 amino acids, which have been predicted to fold into a ␤-propeller domain (Springer, 1997) . A subset of nine integrins incorporates an additional, autonomously folding domain of ϳ200 amino acids, which is inserted between ␤-sheets 2 and 3 of the putative ␤-propeller and is termed the I (inserted) domain. The I domain is present in LFA-1 and the other ␤2 integrins Mac-1, p150,95, and ␣d␤2, as well as in ␣1␤1, ␣2␤1, ␣10␤1, ␣11␤1, and ␣E␤7 (Camper et al., 1998; Dickeson and Santoro, 1998; Velling et al., 1999) . The crystal structures of the I domains of LFA-1, Mac-1, and ␣2␤1 have been solved and show a dinucleotidebinding fold (reviewed by Loftus and Liddington, 1997; Humphries and Newham, 1998 ). An unusual Mg 2ϩ /Mn 2ϩ binding site, termed the metal ion-dependent adhesion site, is located on the "top" of the domain, opposite the face that connects the I domain to the putative ␤-propeller domain.
There is a conserved domain at the N terminus of the ␤ subunit, which is predicted to adopt a fold similar to the ␣ subunit I domain. For I domain-containing integrins there is abundant evidence that this I domain contains the major ligand binding site. Recombinant I domains bind ligand not only with the same specificity as the parental integrin but, in most cases, also in the same cation-dependent manner (reviewed by Dickeson and Santoro, 1998) . The importance of the I domain in ligand binding is further underscored by the fact that mutations within the I domain that affect cation coordination by the metal ion-dependent adhesion site motif abolish ligand binding in the context of the intact integrin. However, for the two I domain-containing integrins, LFA-1 and ␣2␤1, there is also evidence that sequences in the ␣ subunit outside the I domain contribute to ligand binding (Stanley et al., 1994; Dickeson et al., 1997) , and mutagenesis shows that the conserved region of the ␤2 subunit is also important for ligand binding (Goodman and Bajt, 1996) .
LFA-1 interaction with the ICAMs, like many other integrin-ligand interactions, is not constitutive but requires a signaling-induced activation event causing a transient increase in the ability of the integrin to bind ligand. There is some evidence to suggest a role for phosphoinositide 3-kinase (Shimizu and Hunt, 1996) and Ras/MAP kinase activation in LFA-1 adhesion (O'Rourke et al., 1998) . Inactive integrin is maintained in the membrane by association of the membrane proximal sequences of the ␣ and ␤ cytoplasmic tails (Hughes et al., 1996) . As a result of intracellular signal transduction, it is hypothesized that cytoplasmic adaptor proteins cause an altered arrangement or "unhinging" of the ␣ and ␤ cytoplasmic regions, and an active integrin ensues. Integrin activation has been correlated both with higher affinity forms of the receptors, which have undergone a conformational change, and with clusters of laterally associated integrins brought about by cytoskeletal alteration . In vivo, a mixture of both forms probably exists. Whether several types of signals are translated across the membrane or whether bidirectional signals give rise to the final active integrin population is presently unclear. These transiently expressed active forms of integrin are thought to be in equilibrium with nonactive forms. A second phase begins when active integrin engages ligand and signals back into the cell. The "outside-in" signals transduced by the fibronectin binding integrin ␣5␤1 have been well investigated (Miyamoto et al., 1995) , but little is known about the signaling capability of LFA-1.
The high-affinity LFA-1 is characterized by more efficient binding of soluble ICAM-1 and also expression of an epitope recognized by monoclonal antibody (mAb) 24 (Dransfield and Hogg, 1989; Dransfield et al., 1992; . Certain mAbs that bind to the ␣L subunit, such as NKI-L16 (Keizer et al., 1988; van Kooyk et al., 1991) or the ␤2 subunit such as KIM-127 or KIM-185 (Robinson et al., 1992; Andrew et al., 1993) , can also activate LFA-1. The nature of the change in conformation which an integrin such as LFA-1 undergoes to give rise to high-affinity integrin is poorly understood. We have recently found that one requirement for conversion of LFA-1 to the high-affinity form is interdomain movement of the I domain . These findings suggested that the I domain, in addition to providing a ligand binding site, also has a role in activation of the integrin.
Approximately two-thirds of integrins do not have a I domain in their ␣ subunit and the autonomously folding I domains are thought to have been inserted into the proteins during evolution. We therefore hypothesized that removal of the I domain from an integrin should retain expression of heterodimeric integrin and allow investigation of I domain functions that are independent of ligand binding. In this study, for the first time, we have removed the I domain from LFA-1 and have examined how the absence of this domain affects the structure, ligand binding capacity, and other functions of this leukocyte integrin. Although LFA-1 without the I domain can no longer bind its ligands, it has the characteristics of a constitutively active integrin. As an example of its ability to signal into the cell, we show that this I domainminus LFA-1 is active as a mediator of integrin "cross-talk" causing the activation of ␤1 integrins on the same cell.
MATERIALS AND METHODS

Reagents
Restriction and modification enzymes were purchased from Boehringer Mannheim (Mannheim, Germany) or New England Biolabs (Hitchin, United Kingdom). The isolation of ICAM-1Fc, produced as a chimeric protein containing the five extracellular domains of human ICAM-1 fused to a human immunoglobulin G1 (IgG1) Fc sequence has been described before . Vascular cell adhesion molecule-1 (VCAM-1) Fc, produced as a chimeric protein consisting of the two N-terminal domains of human VCAM-1 fused to a human IgG1 sequence, was a gift from both R. Lobb (Biogen, Cambridge, MA) and M. Robinson (Celltech Chiroscience, Slough, United Kingdom). Fibronectin (0.1% solution from human plasma) was purchased from Sigma (Poole, United Kingdom).
Monoclonal Antibodies
TS1/18 (CD18; ␤2), TS2/4 (CD11a; ␣L), TS1/22 (CD11a; ␣L), and P5D2 (CD29; ␤1) (all from American Type Culture Collection, Manassas, VA), and 24 (CD11; anti-␣L, ␣M, ␣X), 38 (CD11a; ␣L), and 7.2R (CD49d; ␣4) were purified from tissue culture supernatant by protein A-Sepharose chromatography by the Imperial Cancer Research Fund Research Production Antibody Service. The following mAbs were generously provided: S6F1 (CD11a; ␣L; C. Morimoto, Dana Faber Cancer Institute, Boston, MA); 10D and 2.6E (CD11a; ␣L; D. Andrew, Amgen, Boulder, CO); and HP1/2 (CD49d; ␣4; R. Lobb, as above). CD18 (␤2) mAbs were obtained as follows: KIM 170, KIM 182, KIM 215, and 6.5E (M. Robinson, as above); GRF1 (F. Garrido, Hospital Universitario Virgen de las Nieves, Granada, Spain); CLB54 (R. van Lier, University of Amsterdam, Amsterdam, The Netherlands); H52 and MHM23 (S.K.A. Law, Oxford University, Oxford, United Kingdom); and 60.3 (Bristol-Meyers Squibb, Seattle, WA). The following activating mAbs were generously provided: NKI-L16 (CD11a; ␣L; Keizer et al., 1988; van Kooyk et al., 1991; Petruzzelli et al., 1995) was obtained from Leukocyte Typing Workshop V (Boston, MA). The ␤1 integrin activation reporter mAbs HUTS-21 (Luque et al., 1996) and 15/7 (Yednock et al., 1995) were kindly provided by C. Cabanas (Universidad Complutense, Madrid, Spain) and T. Yednock (Elan Pharmaceuticals, San Francisco, CA), respectively. All other mAbs, CBR LFA-1/1, CBR LFA1/3, CBR LFA1/7, AZN-L20, AZN-L21, ICII, were obtained from Leukocyte Typing Workshops V (Boston, MA) and VI (Kobe, Japan). G25.2 (CD11a; ␣L) was purchased from Becton Dickinson (Oxford, United Kingdom), and SAM-1 (CD49e; ␣5) was from Eurogenetics (Hampton, United Kingdom).
cDNA Construct
To construct the I domain-deleted LFA-1 ␣ subunit (⌬I-LFA-1), two fragments encoding the N-terminal region through to G 128 (fragment A) and S 319 through to G 441 (fragment B) were generated by PCR amplification from a full-length cDNA clone, which had been subcloned into the pZErO-1 vector (Invitrogen, Leek, The Netherlands) (pZ-LFA-1). The necessary changes in the DNA sequence were designed such that the original amino acid sequence was retained. The 3Ј primer for fragment A and the 5Ј primer for fragment B contained extensions to add in-frame restriction sites for HindIII. The primers were as follows (with restriction enzyme sites given in bold type): fragment A 5Ј (hybridizing in vector sequence): 5Ј-TCAAGCTATGCATCAAGCTT-3Ј; fragment A 3Ј: 5Ј-AGGTCTA-AGCTTCCCTTG-3Ј; fragment B 5Ј: 5Ј-GGACCTGACAAGCT-TCAA-3Ј; and fragment B 3Ј: 5Ј-CTTGGTCCACGTCGAC-3Ј. Fragment A (cut with NsiI and HindIII) and fragment B (cut with HindIII and SalI) were subcloned together into pZ-LFA-1 (cut with NsiI and SalI) after the corresponding wild-type (wt) fragment was removed. DNA sequencing was carried out using an automated sequencer (PE Biosystems, Warrington, United Kingdom). The cDNA encod-ing ⌬I-LFA-1 was finally subcloned into the expression vector pcDNA3.1/Zeo (Invitrogen).
Cell Lines and Cell Culture
The human T lymphoma cell line clone J-␤2.7, derived from Jurkat cells by mutagenesis (Weber et al., 1997) , was a gift from L. Klickstein (Brigham and Women's Hospital, Boston, MA). Cells were maintained in RPMI 1640 medium supplemented with 10% FCS (Life Technologies, Paisley, United Kingdom) (complete medium). J-␤2.7 transfectants were maintained in complete medium supplemented with 250 g/ml Zeocin (Invitrogen).
cDNA Transfection and Generation of Stable Cell Lines
J-␤2.7 cells (8 ϫ 10 6 per transfection) in log phase growth were washed, resuspended in 0.7 ml RPMI 1640 medium, and mixed with 25 g of wt LFA-1 or ⌬I-LFA-1 DNA. Electroporation was carried out at 320 V and 960 F. After 48 h of culture in complete medium, the medium was supplemented with 250 g/ml Zeocin (Invitrogen). Cells expressing ⌬I-LFA-1 were enriched for the highest expressing population by sterile cell sorting on a FACS Vantage cell sorter (Becton Dickinson, Oxford, United Kingdom) using anti-LFA-1 mAb G25.2. From this population clones were obtained by sterile sorting of single cells. Cells expressing wt LFA-1 were cloned by limiting dilution.
Flow Cytometric Analysis
Cells (2 ϫ 10 5 ) were incubated with primary mAb in 100 l of PBS and 0.2% BSA for 20 -30 min on ice. Purified mAbs were used at 10 g/ml; ascites were used at a 1:100 dilution. Incubation with mAb NKI-L16 was in HEPES buffer (20 mM HEPES, 140 mM NaCl, 2 mg/ml glucose) plus 1 mM Ca 2ϩ . For mAb 24 detection, cells were incubated with mAb 24 at 37°C in complete medium. Incubation with mAbs 15/7 and HUTS-21 was at room temperature in HEPES buffer with or without the specified concentrations of MnCl 2 . After the incubation with primary mAb, cells were washed three times with PBS and BSA and incubated with FITC-conjugated goat antimouse IgG (Sigma) for 30 min on ice. After three washes as above, the cells were resuspended in cold PBS and BSA and analyzed on a FACScan flow cytometer (Becton Dickinson).
Cell Adhesion to ICAM-1Fc
Immulon 3 96-well plates (Dynatech Technologies, Chantilly, VA) were coated overnight at 4°C with goat anti-human IgG (Fc specific; Sigma) at 20 g/ml. ICAM-1Fc was added at 10 g/ml in PBS for 2 h at 37°C. Nonspecific sites were then blocked with 2.5% BSA in PBS for 1 h, and the plates were washed in HEPES buffer. Cells were labeled with 2.5 M 2Ј,7Ј-bis (carboxyethyl)-5(6Ј)-carboxyfluorescein acetomethyl ester (Calbiochem, Nottingham, United Kingdom) in HEPES buffer for 30 min at 37°C and then washed. Fifty microliters of cells at 3 ϫ 10 6 /ml were added to the ICAM-1Fc-coated plates in the presence of 50 l of the appropriate adhesion-inducing stimuli. Phorbol 12,13-dibutyrate (PdBu; final concentration, 100 nM) and mAbs were diluted in RPMI (10 g/ml final concentration for mAb 24, 5 g/ml final concentrations for mAbs KIM 127, KIM 185, and NKI-L16). Mn 2ϩ (1 mM final concentration) was diluted in HEPES buffer; Mg 2ϩ (up to 5 mM final concentration) was diluted in HEPES buffer containing EGTA (1 mM final concentration). Plates were incubated on ice for 15 min, followed by a 30-min incubation at 37°C. Nonadherent cells were washed off by two washes in warmed HEPES buffer containing 1 mM Mg 2ϩ and Ca 2ϩ . Adhesion was quantified by a fluorescence plate reader (Fluoro-scan II; Labsystems, Basingstoke, United Kingdom).
Fibronectin-or VCAM-1Fc-coated Bead Binding Assays
Fibronectin-and VCAM-1-coated bead binding assays were adapted from the method of Porter and Hogg (1997) . Three-micrometer latex beads (Sigma) were coated with 5 g/ml fibronectin or 1 g/ml VCAM-1, blocked in 1% BSA in PBS, washed, and resuspended in complete medium. Multiwell Lab-Tek chamber slides (Nunc, Naperville, IL) were coated overnight at 4°C with rabbit anti-mouse Ig (Dako, Ely, United Kingdom) at 35 g/ml. mAb UCHT2 (CD5) was added at 10 g/ml in PBS for 3 h at room temperature. Wells were blocked with 1% BSA in PBS for 1 h and then washed in complete medium. Cells (200 l of 6 ϫ 10 5 /ml, in complete medium) were added in the presence or absence of 100 l of mAbs or PdBu (4ϫ final concentration in complete medium) and allowed to settle for 30 min on ice. mAb 24 was used at a final concentration of 5 g/ml; mAb NKI-L16 at 0.5 g/ml; PdBu at 100 nM; cytochalasin D at 5 M; and blocking mAbs at 10 g/ml. Ligand-coated beads were added at a 100:1 beads:cell ratio in 100 l. After a 15-min incubation on ice, the Lab-Tek slides were incubated for 90 min at 37°C. Unbound beads and cells were removed by four washes in warm RPMI. Cells were fixed with 1% formaldehyde in PBS for 20 min at room temperature, and then stained with hematoxylin. Beads and cells were counted per high-power field (40ϫ oil immersion objective; Carl Zeiss, Thornwood, NY). The number of beads per 100 cells was determined as the mean of five high-power fields Ϯ SD.
Soluble VCAM-1Fc Binding Assay
Binding of soluble VCAM-1Fc was adapted from the method of Jakubowsky et al. (1995) . Aliquots of 2 ϫ 10 5 cells were incubated with VCAM-1Fc in HEPES buffer plus the indicated concentrations of MnCl 2 and 0.02% NaN 3 for 30 min at room temperature. Cells were then washed twice in the incubation buffers containing the same MnCl 2 concentrations and incubated with FITC-conjugated goat anti-human IgG (Fc specific; Sigma) for 30 min on ice (in HEPES buffer plus 0.2% BSA). After three washes, cells were fixed in 2% formaldehyde and PBS. VCAM-1Fc binding was analyzed by a FACScan flow cytometer (Becton Dickinson) to give mean fluorescence intensity units.
Confocal Microscopy
Aliquots of 1 ϫ 10 6 cells were incubated with mAb 7.2R or SAM-1 in RPMI 1640 medium for 30 min on ice and then washed three times in PBS. To prevent antibody-induced clusters, cells were fixed in 1% paraformaldehyde and PBS for 30 min on ice before a second incubation with Alexa 488-conjugated goat anti-mouse IgG (Molecular Probes, Eugene, OR) for 30 min on ice. After three washes, cells were attached to poly-l-lysine-coated 13-mm round glass coverslips, fixed in 3% formaldehyde and PBS, and mounted onto slides in Mowiol (Calbiochem) dissolved in the antifade solution Citifluor (UKC Chemical Laboratory, Canterbury, United Kingdom). Fluorescence was analyzed using a Zeiss LSM 510 confocal laser scanning microscope equipped with a 63ϫ, numerical aperture 1.4 objective, with an argon laser (wavelength, 488 nm). Cell surface distribution was evaluated by taking horizontal optical sections at 0.35-m vertical steps throughout the whole height of representative cells. Images of optical sections (512 ϫ 512 pixels) were digitally recorded, and their projections were generated using the LSM 510 program. The resulting images were processed using Adobe (Mountain View, CA) Photoshop software. 
RESULTS
Expression of I Domain-deleted LFA-1 in Jurkat-
␤2.7 Cells
To study the function of LFA-1 minus the I domain, an ␣L subunit cDNA construct was generated by deleting DNA sequences predicted to encode the I domain of LFA-1 according to the model for the homologous ␤2 integrin Mac-1 (Springer, 1997;  Figure 1A ; see MATERIALS AND METH-ODS for details). The boundary of the domain was chosen such that the predicted disulfide bond arrangement for intact LFA-1 was not altered (i.e., the conserved C 125 residue, which is predicted to form a disulfide bond with C 94 , was retained). The I domain-deleted protein, termed ⌬I-LFA-1, lacked the sequence N 129 -T 318 of the full-length LFA-1 ␣ subunit but did not contain any additional sequences. cDNAs for ⌬I-LFA-1 and wt LFA-1 were stably transfected into Jurkat-␤2.7 cells, which are deficient for the endogenous LFA-1 ␣ subunit but retain a functional ␤2 subunit (Weber et al., 1997) . This ␤2 subunit is only transported to the cell surface upon heterodimerization with transfected ␣L. For both wt LFA-1-and ⌬I-LFA-1-expressing cells, several clones were selected that exhibited comparable levels of surface expression as detected by immunoprecipitation (our unpublished results) and flow cytometry (see following). At least two independent clones were used for each experiment.
Expression of mAb Epitopes by ⌬I-LFA-1 and wt LFA-1
We analyzed cell surface expression of LFA-1 ␣ and ␤ subunit epitopes on representative clones of wt LFA-1-and ⌬I-LFA-1-expressing cells ( Figure 1B ). Both wt LFA-1-and ⌬I-LFA-1-expressing cells showed very similar fluorescence levels of the non-I domain-specific ␣L mAb G25.2 as well as the ␤2-specific mAb TS1/18, indicating that the transfected ␣ subunits and the endogenous ␤2 subunit were transported to the cell surface to the same extent in both cell lines. As expected, in contrast to wt LFA-1-expressing cells, ⌬I-LFA-1-expressing cells did not react with the I domain-specific mAb 38. The reactivity of a panel of mAbs against the LFA-1 ␣L and ␤2 subunits was assessed (Table 1) . ⌬I-LFA-1 reacted with all of the tested ␣L subunit mAbs that map outside the I domain and, as expected, did not react with any I domainspecific mAbs including the mAb CBR LFA-1/1 whose epitope overlaps the I and ␤-propeller domains (Huang and Springer, 1995) . Epitopes for all the tested ␤2 subunit-specific mAbs were present on ⌬I-LFA-1 and were expressed to the same level as on wt LFA-1 (except activating mAbs, see below). Taken together, these results show that ⌬I-LFA-1 is expressed on the cell surface, forms heterodimers with endogenous ␤2 subunit, and is folded for correct mAb recognition by a wide range of different anti-LFA-1 mAbs.
The I Domain of LFA-1 Is Necessary for Adhesion to ICAM-1
To test whether ⌬I-LFA-1 showed detectable ligand binding activity, adhesion assays using the LFA-1 ligands ICAM-1 ( Figure 1C ) and ICAM-3 (our unpublished results) were performed. Adhesion-inducing agents covered a range of stimuli activating the integrin from the outside (i.e., divalent cations Mn 2ϩ or Mg 2ϩ /EGTA, activating mAbs KIM 127 [Robinson et al., 1992] , KIM 185 [Andrew et al., 1993] , or NKI-L16 [van Kooyk et al., 1991] ), or a combination of activating mAbs and the phorbol ester PdBu, which activates LFA-1 by triggering signal transduction pathways from within the cell. Although wt LFA-1 adhered to both ligands under all the conditions tested, ⌬I-LFA-1 did not adhere at all to ICAM-1 or ICAM-3. A more sensitive adhesion assay, which uses buoyancy rather than washing to remove nonadherent cells (Goodwin and Pauli, 1995) , also failed to detect any adhesion of ⌬I-LFA-1-transfected cells to ICAM-1 (our unpublished results). As a third approach, ICAM-1-coated latex beads were added to cells together with LFA-1-activating stimuli, but ⌬I-LFA-1-transfected cells failed to show any specific interactions with ICAM-1-coated beads, even after incubation times as long as 24 h (our unpublished results). wt LFA-1-expressing cells were strongly positive in both of these assays, which detect weak adherence reactions. Taken together, these results are consistent with the interpretation that the I domain of LFA-1 contains the major ligand binding site and is essential for the binding reaction of LFA-1 to ICAM-1. 
Cells were stained with the indicated mAbs for 20 min on ice, washed, stained with FITC-conjugated goat anti-mouse IgG and analyzed by flow cytometry. ␣L non-I dom, epitope mapped to ␣L outside the I domain; ␣L I dom/non-I dom, epitope mapped to region overlapping I domain and ␤-propeller domain; ␣L I dom, epitope mapped on ␣L I domain. Ϫ, staining not greater than that seen with secondary mAb alone (see Fig. 1B ). ϩ, positive staining, usually similar to that seen in Fig 1B. Staining of ⌬I-LFA-1-expressing cells always to same extent as that seen on wt LFA-1-expressing cells relative to G25.2 expression. Data are representative of at least three determinations on at least two different clones.
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⌬I-LFA-1 Expresses Higher Levels of Activation Epitopes than wt LFA-1
Certain activating mAbs (with epitopes outside the I domain) can promote LFA-1 ligand binding activity from the outside of the cell, and this is thought to involve conformational changes in the integrin, which are either induced or stabilized by these mAbs . It was of interest to investigate whether removal of the I domain from LFA-1 altered the expression of epitopes detected by several activating anti-␤2 mAbs and the activating anti-␣L mAb NKI-L16. Compared with wt LFA-1-expressing cells, ⌬I-LFA-1-expressing cells showed approximately five times higher fluorescence levels of the ␣L mAb NKI-L16 and the ␤2 mAb KIM 127 and six to eight times higher fluorescence levels of the ␤2 mAb 240Q (Figure 2 ). All three of these mAb epitopes were expressed at low levels on wt LFA-1-expressing cells. Expression of three other activating ␤2 mAbs, KIM 185, MEM48, and CBR LFA-1/2, was also enhanced on ⌬I-LFA-1-expressing cells compared with wt LFA-1-expressing cells (our unpublished results). The mAb 24 epitope, which can be induced by divalent cations Mg 2ϩ or Mn 2ϩ , reflects a conformational change in LFA-1 characteristic of a higher-affinity receptor and is considered to act as an activation reporter (Dransfield and Hogg, 1989; Dransfield et al., 1992; . This epitope was not expressed by the wt LFA-1-expressing cells, but, as for the activation mAbs, there was enhanced expression on the ⌬I-LFA-1-expressing cells (Figure 2) . Therefore, certain epitopes, all of which are associated with LFA-1 activation, are more highly expressed when the I domain is removed.
Higher Ligand Binding Activity of ␣4␤1 and ␣5␤1 on ⌬I-LFA-1-expressing Cells than on wt LFA-1-expressing Cells
Although ⌬I-LFA-1 was deficient in ligand binding, it exhibited enhanced expression levels of activation epitopes and the activation reporter epitope 24. These findings suggested that LFA-1 without its I domain was in an "active" conformation, which might be able to transmit signals into the cell. LFA-1 has been shown to regulate the ligand binding capacity of ␤1 integrins through intracellular signaling termed cross-talk (Porter and Hogg, 1997) . To test the possibility that ⌬I-LFA-1 was active in signal transduction, we therefore asked whether the presence of ⌬I-LFA-1 on J-␤2.7 cells influenced the basal ligand binding activity of ␤1 integrins in these cells. Fibronectin was used as a ligand that is recognized by both ␣4␤1 and ␣5␤1, and VCAM-1 was used as a ligand for ␣4␤1 alone. Figure 3 shows that nontransfected J-␤2.7 cells and three independent clones expressing wt LFA-1 each bound comparable numbers of fibronectin-or VCAM-1-coated beads per cell. By comparison, all four of the tested ⌬I-LFA-1 clones exhibited significantly higher bead binding activity. Fibronectin and VCAM-1 binding on cells expressing wt LFA-1 or ⌬I-LFA-1 was completely blocked by the blocking anti-␤1 mAb P5D2 (see below; our unpublished results).
To analyze whether this increase in fibronectin and VCAM-1 binding activity might be explained by enhanced expression of ␣4␤1 or ␣5␤1 in clones expressing ⌬I-LFA-1, the surface expression of these integrins was measured by flow cytometry. Similar surface expression levels of ␣4␤1 and ␣5␤1 were found on the parental J-␤2.7 cells ( Figure 4A ) and on the clones expressing wt LFA-1 (Figure 4 , B-D) as well as ⌬I-LFA-1 (Figure 4, E-H) . Therefore, the activity and Figure 2 . Expression of epitopes recognized by activating mAbs NKI-L16 (anti-␣L), KIM 127 (anti-␤2), 240Q (anti-␤2), and 24 (anti-␣L activation reporter) on J-␤2.7 cells expressing wt LFA-1 or ⌬I-LFA-1. Cells were stained on ice with the relevant mAbs followed by FITC-conjugated goat anti-mouse IgG and analysis by flow cytometry. Dotted lines, negative control; thick lines, mAb G25.2; filled histograms, activating mAbs. Data for each set of mAbs are from experiments conducted in parallel, and one experiment representative of three is shown.
not the surface expression of ␣4␤1 and ␣5␤1 was up-regulated in clones expressing ⌬I-LFA-1.
Activating ⌬I-LFA-1 by mAbs Further Up-regulates the Function of ␤1 Integrins
To confirm that the enhanced ␤1 integrin activity of the cells expressing ⌬I-LFA-1 was directly linked to the presence of ⌬⌱-LFA-1 and not caused by some coincidental alteration in these transfectants, we analyzed whether direct targeting of ⌬I-LFA-1 by anti-LFA-1 mAbs NKI-L16 or 24 would influence fibronectin binding ( Figure 5 ). On cells expressing ⌬I-LFA-1, stimulation with either of these mAbs led to a further increase in fibronectin binding above the constitutive level, which was comparable with stimulation of the cells with PdBu. Cells expressing wt LFA-1 were stimulated by PdBu to bind fibronectin, as expected, but mAbs 24 or NKI-L16 had no effect. All fibronectin binding was completely blocked by the ␤1-specific mAb P5D2 or by a combination of mAbs against ␣4 and ␣5 integrins (our unpublished results; see Figure  7 ). Therefore, stimulation of ⌬I-LFA-1 with mAbs that either bind to or stabilize only active LFA-1 led to an increase in fibronectin binding mediated by ␣4␤1 and/or ␣5␤1. These results further established that ⌬I-LFA-1 had a direct role in signaling into the cells.
⌬I-LFA-1 Does Not Cause an Increase in ␣4␤1 Integrin Affinity
We next wanted to characterize the enhanced activated state of the ␤1 integrins on cells expressing ⌬I-LFA-1. As the ability to bind soluble ligand is a measure for integrin affinity, we first investigated the state of soluble VCAM-1 binding by ␣4␤1 on ⌬I-LFA-1-and wt LFA-1-expressing cells. Over a range of Mn 2ϩ concentrations no differences were observed between the two types of cells in their ability to bind VCAM-1 (held constant at 10 nM) ( Figure 6A ). Again, no significant differences in VCAM-1 binding between the two types of cells were observed when the VCAM-1 concentration was varied and the Mn 2ϩ concentration was held constant at 1 mM ( Figure 6C ). The titration curves for both cell lines show bivalent VCAM-1 binding between 1 and 10 nM followed by monovalent binding to the level of 5 M (Jakubowsky et al., 1995; Lobb et al., 1995; Pujades et al., 1997) .
To examine whether ⌬I-LFA-1 affects the conformation of the ␤1 integrins, we used the mAbs HUTS-21 (Luque et al., 1996) and 15/7 (Yednock et al., 1995) , the epitopes for which are induced by Mn 2ϩ . Epitope expression of these mAbs is also a measure of ␤1 integrin affinity. There was a direct correlation between Mn 2ϩ concentration and expression of the epitopes, as expected, but no difference in epitope expression between the ⌬I-LFA-1-and wt LFA-1-expressing cells ( Figure 6B ). It is of interest that the ␤1 epitope curves mirrored the VCAM-1 binding curves after titration of Mn 2ϩ ( Figure 6A ). Taken together, these results indicate that there was no increase in ␤1 integrin affinity or change in conformation as detected by mAbs HUTS-21 and 15/7 on cells expressing ⌬I-LFA-1 compared with wt LFA-1-expressing cells.
The Increased Activity of ␤1 Integrins in ⌬I-LFA-1-expressing Cells Is Dependent on an Intact Cytoskeleton
To gain some insight into the nature of the signals transduced by ⌬I-LFA-1-expressing cells, we analyzed the effect of the cytoskeleton-disrupting drug cytochalasin D ( Figure  7) . On wt LFA-1-expressing cells, cytochalasin D had no effect on fibronectin or VCAM-1 binding. However, on ⌬I-LFA-1-expressing cells, cytochalasin D inhibited both fibronectin and VCAM-1 binding to the same basal levels exhibited by wt LFA-1-expressing cells. The specificity of the ␤1 integrin-mediated adhesion is shown by complete blocking of fibronectin binding of both cell lines by a combination of mAbs against ␣4 and ␣5 integrins and partial blocking by the anti-␣5 blocking mAb SAM-1 alone. VCAM-1 binding was completely blocked by the anti-␣4 blocking mAb HP1/2 and not affected by the anti-␣5 mAb SAM-1. The results with cytochalasin D imply a role for the cytoskeleton itself or processes dependent on the cytoskeleton in the signaling, which gives rise to enhanced ␤1 integrin-mediated function in ⌬I-LFA-1 expressing cells.
⌬I-LFA-1 Causes an Increase in ␤1 Integrin Clustering
A characteristic feature of activated integrin that is dependent on the cytoskeleton is integrin clustering. We therefore assessed the state of integrin clustering on wt and ⌬I-LFA-1-expressing cells using confocal laser microscopy. As illustrated in Figure 8 , on cells expressing ⌬I-LFA-1, ␣4␤1 was found in large clusters on the cell surface. In contrast, on wt-LFA-1-expressing cells, ␣4␤1 was more diffusely distributed (Figure 8, A and C vs. B and D) . Staining for ␣5␤1 on cells expressing ⌬I-LFA-1 showed a significant increase in signal strength compared with cells expressing wt LFA-1, indicating that ␣5␤1 is also more clustered on ⌬I-LFA-1 expressing cells (Figure 8, E and F) . Pretreatment of ⌬I-LFA-1-expressing cells with 5 M cytochalasin D reduced clustering of ␣4␤1 and ␣5␤1 to levels observed on wt LFA-1-expressing cells, whereas cytochalasin D had no effect on the distribution of these ␤1 integrins on wt LFA-1-expressing cells (our unpublished results). Therefore, ⌬I-LFA-1 appears to signal through the cytoskeleton to cause constitutive ␤1 integrin clustering.
DISCUSSION
In this study, LFA-1 lacking the I domain (⌬I-LFA-1) was expressed in the ␣L-deficient Jurkat T cell line, J-␤2.7, which allowed analysis of LFA-1-dependent functions in a lymphocyte background. The major findings of this study are 1) ⌬I-LFA-1 is expressed as an ␣␤ heterodimer on the cell surface, demonstrating that the I domain is not necessary for heterodimer formation; 2) the I domain of LFA-1 is essential for ligand binding, because ⌬I-LFA-1 showed no detectable ligand binding activity to ICAM-1 or ICAM-3; 3) removal of the I domain leads to enhanced expression of activation epitopes as well as expression of the activation reporter epitope 24, which suggests that the I domain regulates conversion to the high-affinity conformation; 4) ⌬I-LFA-1 signals constitutively into the cell, as illustrated by the activation of ␤1 integrins on the same cell through integrin crosstalk; the nature of the signals transmitted by ⌬I-LFA-1 is dependent on an intact actin cytoskeleton; and 5) ⌬I-LFA-1 does not signal an increase in affinity of the ␤1 integrins but does cause enhanced integrin clustering.
⌬I-LFA-1 was detected on the cell surface by a number of different anti-LFA-1 mAbs, indicating correct folding of the ␣ and ␤ subunits in the absence of the I domain. In fact, all tested mAb epitopes outside the I domain were expressed by ⌬I-LFA-1 and wt LFA-1 to a similar extent. The specific expression of epitopes dependent on association of ␣L with ␤2 (e.g., TS2/4 and TS1/18; Dustin et al., 1992) indicates that ⌬I-LFA-1 formed heterodimers with the endogenous ␤2 subunit on the cell surface. Therefore, correct folding of the ␤-propeller and C-terminal domains of the ␣L subunit and heterodimerization of ␣L with ␤2 are independent of the I domain. In agreement, another study showed that, in the context of intact LFA-1, folding of the ␤-propeller domain was independent of the I domain .
The I domain contains the major ligand binding site in LFA-1. However, because additional sites contributing to ligand binding are predicted in both the ␣L subunit (Stanley et al., 1994) and the ␤2 subunit (Goodman and Bajt, 1996; Goodman et al., 1998) , it was possible that an I domaindeleted LFA-1 might bind ligand similarly to a non-I domain-containing integrin. The data in the present study clearly demonstrate that there is no residual ICAM-1 or ICAM-3 ligand binding capacity in ⌬I-LFA-1. Therefore, the additional sites, although participants in ligand binding in Although LFA-1 without an I domain has lost its capacity to bind ligand, a significant feature of ⌬I-LFA-1 is the enhanced expression of mAb epitopes, which are associated with activation of LFA-1. For example, the Ca 2ϩ -dependent ␣L-specific NKI-L16 epitope is expressed by a subset of LFA-1 that is primed for activation . In addition, the activation epitopes detected by KIM 127, KIM 185 (Ortlepp et al., 1995), MEM48, and 240Q (McDowall, unpublished data) are also expressed by subsets of total cellular LFA-1 on other leukocytes. The fact that these activation epitopes are expressed only at a low level by intact LFA-1, as in our study, suggests that these sites are masked but exposed upon activation. mAbs KIM 127, KIM 185, MEM48, and CBR LFA-1/2, have been mapped to the cysteine-rich region of the ␤2 subunit . Thus, in addition to the ␣ subunit, the conformation of the cysteine-rich region in the ␤2 subunit may be altered on ⌬I-LFA-1 compared with wt LFA-1. Alternatively, removal of the I domain could lead to unmasking of the cysteine-rich region. This latter explanation is favored by the finding that KIM 127 recognizes the immature unassociated ␤2 subunit but not the mature ␤2 subunit of the ␣L␤2 heterodimer . It is of interest that ligand binding and integrin activation of ␣5␤1 integrin has been linked to uncovering of the ␤1 cysteine-rich region (Tsuchida et al., 1998) .
In the present study, wt LFA-1 showed no constitutive expression of the activation reporter mAb 24 epitope, whereas ⌬I-LFA-1 cells expressed this epitope. Expression of the 24 epitope is a hallmark of higher-affinity LFA-1, a form of the receptor that is capable of binding soluble ligand Ganpule et al., 1997) . In vivo this highaffinity LFA-1 conformation is not constitutively found on resting leukocytes, but increased epitope expression has been correlated with human T cell activation in secondary lymphoid tissues (Picker et al., 1993) . Expression of this activation reporter epitope further confirmed the activated status of ⌬I-LFA-1 compared with wt LFA-1.
Although ⌬I-LFA-1 could no longer bind ligand, it was of interest to know whether the active conformation of ⌬I-LFA-1 was correlated with signal transduction into the cell. The signaling capabilities of LFA-1 have usually been tested by analyzing LFA-1 functions as a costimulator in conjunction with other membrane receptors, which has made it difficult to resolve whether LFA-1 can signal independently. However, a signaling activity of LFA-1 that is dependent on LFA-1 alone is the ability to influence the activity of other integrins such as ␣4␤1 and ␣5␤1, termed cross-talk (Porter and Hogg, 1997) . A characteristic of the ⌬I-LFA-1-expressing cells is constitutively elevated fibronectin and VCAM-1 binding activity mediated by the ␤1 integrins ␣4␤1/␣5␤1 (fibronectin binding) and ␣4␤1 alone (VCAM-1 binding). Evidence that this was functionally related to the presence of ⌬I-LFA-1, and not some coincidental activity, was shown by the additional enhanced ␤1 integrin activity of ⌬I-LFA-1-expressing cells after exposure to the LFA-1-specific mAbs NKI-L16 and 24.
How integrins effect cross-talk to other integrins has not yet been defined in molecular terms. However, distinctive features ascribed to active integrins fall into two categories. In response to intracellular signals, integrins such as ␣IIb␤3 can alter their conformation and bind ligand with higher affinity (Hato et al., 1998) . Alternatively, integrins cluster in response to intracellular signals and bind ligand with greater adhesive strength Stewart et al., 1998) . We found no evidence for an affinity alteration of ␣4␤1 on ⌬I-LFA-1-expressing cells, as assessed by binding of soluble ligand VCAM-1 or expression of ␤1 subunit reactive HUTS-21 and 15/7 activation epitopes, which register the active conformation particularly of ␣4␤1 (Bazzoni et al., 1998) . However, the ␤1 integrins ␣4␤1 and ␣5␤1 were observed to be in a constitutively highly clustered state on ⌬I-LFA-1-expressing cells. These results contrast with the Characteristics of I Domain-deleted LFA-1 dominant inhibition that ␣IIb␤3 had on the affinity of ␣5␤1 .
The fact that cytochalasin D blocked the enhanced activity and the clustering of ␤1 integrins on ⌬I-LFA-1-expressing cells implies that the cytoskeleton or processes dependent on the cytoskeleton are targets of ⌬I-LFA-1-mediated signaling. These findings suggest that active LFA-1 might reorganize the cytoskeleton in a manner that instructs other integrins to link into it, a process that happens during cell migration (Felsenfeld et al., 1996) . Another possibility to be considered is that clustering may occur after removal of cytoskeletal constraints by the signaling integrin.
In addition to our findings, another example of positive integrin cross-talk involves activation of ␣2␤1 by the interaction of ␣5␤1 with ligand (Pacifici et al., 1994) . In contrast, other examples of inter-integrin communication can be termed "trans-dominant inhibition" because of the negative effect on target integrin function (Blystone et al., 1994; Blystone et al., 1995; Huhtala et al., 1995; DiazGonzalez et al., 1996; Hodivala-Dilke et al., 1998) . In fact, LFA-1-mediated cross-talk in primary T cells was detected as a negative effect on ␣4␤1 function (Porter and Hogg, 1997) . These conflicting results raise the issue as to why there is positive regulation of integrin function in some situations and, in others, negative regulation. It has been suggested that a prerequisite for negative regulation is high expression of the "dominating" integrin (DiazGonzalez et al., 1996) . The choice between positive or negative cross-talk may depend on the availability of adaptor proteins for cytoskeletal connections or components of critical signaling pathways. Potentially highly expressed integrins such as ␣II␤3 transfected into Chinese hamster ovary cells , ␣3␤1 on keratinocytes (Hodivala-Dilke et al., 1998) , or LFA-1 on cultured primary T cells (Porter and Hogg, 1997 ) might sequester such essential adaptor or signaling molecules. However, in other situations such as described in this study, in which the activating integrin is expressed at relatively low levels, the adaptor-signaling protein(s) may be generated in excess amounts and available to other integrins on the same cell. Signaling enzymes that have been implicated in cross-talk are protein kinase C (Pacifici et al., 1994) and calmodulin-dependent kinase II (Blystone et al., 1999) . Future work will be required to investigate whether these kinases or other signaling components are activated by LFA-1 to operate through the cytoskeleton to cause clustering of "target" integrins.
In summary, LFA-1 expressed without its I domain does not bind its ICAM ligands, has the features of an activated integrin, and appears to signal constitutively back into the T cell. The altered conformation of ⌬I-LFA-1 compared with wt LFA-1 suggests that a quarternary structural change has occurred in the integrin ectodomain, which could alter the configurations of the ␣L and ␤2 cytoplasmic domains, leading to a constitutively active signaling integrin. Alternatively, the absence of the I domain might alter the associations of LFA-1 with other membrane proteins. We have recently shown that the I domain participates in interdomain movement upon activation , which could be a prerequisite for the subsequent activated conformation. Thus, as well as binding ligand, the I domain controls activation of LFA-1 extracellularly and complements the regulation of adhesiveness provided by the cytoplasmic sequences of both subunits (O'Toole et al., 1994; Lu and Springer, 1997) . We show here that the activation of LFA-1 has a major effect on the activity of ␤1 integrins on the same T cell membrane. Thus at least some integrins appear not to operate in isolation but, as a consequence of their activation status, directly influence the activity of other classes of integrin on the same cell.
